兰州佛慈制药股份有限公司 内部控制审计报告 众环审字(2025)0205905号 审计报告第1 页共 3 页 电话 Tnl 02 侮■ [ax: 027-85424329 内部控制审计报告 兰州佛慈制药股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我们审计了兰 州佛慈制药股份有限公司（以下简称"佛慈制药公司"）2024 年 12 月 31 日的财务报告内 部控制的有效性。 众坏审字(2025)0205905 号 一、佛慈制药公司对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指 引》的规定,建立健全和有效实施内部控制,并评价其有效性是佛慈制药公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表审计意见, 并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 我们认为，佛慈制药公司于 2024 年 12 月 31 日按照《企业内部控制基本规范》和相关 规定在所有重大方面保持了有效的财务报告内部控制。 普通合伙) 中审 中国注册会计师: 中国注册会计 ...

Financial Performance - The company's operating revenue for 2024 was ¥980,225,387.73, a decrease of 15.73% compared to ¥1,163,134,313.96 in 2023[17]. - The net profit attributable to shareholders for 2024 was ¥60,069,813.05, down 10.60% from ¥67,189,706.97 in 2023[17]. - The net cash flow from operating activities decreased by 40.68% to ¥38,984,923.46 in 2024 from ¥65,714,299.86 in 2023[17]. - Basic earnings per share for 2024 were ¥0.1176, a decline of 10.64% from ¥0.1316 in 2023[17]. - Total assets at the end of 2024 were ¥2,469,785,308.07, a decrease of 2.31% from ¥2,528,102,214.36 at the end of 2023[17]. - The net assets attributable to shareholders increased by 2.55% to ¥1,789,888,294.75 at the end of 2024 from ¥1,745,370,807.77 at the end of 2023[17]. - The company reported a total of 467 drug approval numbers, with 10 exclusive products in its portfolio[31]. - The overall performance of the pharmaceutical manufacturing industry in 2024 is expected to remain flat compared to 2023, with a 1.1% decline in total profits[26]. - The company achieved operating revenue of 98,022.54 million yuan in 2024, a decrease of 15.73% compared to the previous year[37]. - The total profit amounted to 6,913.95 million yuan, down 15.31% year-on-year, while the net profit attributable to shareholders was 6,006.98 million yuan, a decrease of 10.60%[37]. Market and Product Development - The company is positioned in the traditional Chinese medicine sector, benefiting from government support and increasing health awareness among the population[27]. - In 2024, various national policies were introduced to promote the development of traditional Chinese medicine, emphasizing innovation and quality improvement[28][29]. - The company launched over 30 health tea products, including "Xiao Yao Soup" and "Qing Qing Peach Blossom Drink"[37]. - The company developed 14 new patents, with 3 invention patents and 1 design patent approved, and received a second-class award for patents in Gansu Province[39]. - The company is conducting research on three exclusive traditional Chinese medicine products, with the first phase completed and the second phase underway[66]. - Five health food products have been developed under the concept of food-medicine homology, contributing to the company's health industry expansion[66]. - The company aims to leverage Gansu's local medicinal resources to enhance its traditional Chinese medicine health industry development[66]. Operational Efficiency and Cost Management - The company has reduced water, electricity, and gas consumption by 7.0%, 2.8%, and 9.1% respectively, saving approximately 1.41 million yuan[40]. - The company’s inventory increased by 37.18% to ¥197,736,309.13, attributed to adjustments in production structure and planning[58]. - Research and development expenses amounted to ¥29,284,084.57, reflecting a decrease of 5.31% from the previous year[64]. - The company’s total operating costs for the pharmaceutical sector were ¥680,513,278, a decrease from ¥801,838,651 in the previous year[60]. - Sales expenses decreased by 24.51% to ¥116,044,604.78, while management expenses fell by 18.19% to ¥68,957,995.30[64]. Governance and Management - The company has established a value management system to enhance investment value and protect stakeholders' rights, approved by the board on April 25, 2025[97]. - The company has implemented a "Quality and Return Dual Improvement" action plan, although details on its disclosure were not provided[98]. - The company governance structure complies with relevant laws and regulations, ensuring proper operation and protection of shareholder rights[100]. - The board of directors was re-elected on August 14, 2024, following a fair and transparent selection process[101]. - The supervisory board was also re-elected on August 14, 2024, maintaining compliance with legal requirements[101]. - The company operates independently from its controlling shareholder in terms of business, personnel, assets, and finance, ensuring a complete and autonomous operational system[104]. - The company has established an independent financial department with its own accounting system, ensuring independent financial decision-making[105]. Shareholder Engagement and Profit Distribution - The company plans to distribute a cash dividend of ¥0.12 per 10 shares, based on a total of 510,657,000 shares[5]. - The profit distribution policy for the reporting period was maintained without changes, and the company has a three-year shareholder return plan for 2024-2026[133]. - The company reported a total of 60,069,813.05 yuan in distributable profits for the reporting period[135]. - The cash dividend distribution accounted for 100% of the total profit distribution amount[135]. - The company distributed a total of 15.32 million CNY in cash dividends during the reporting period, sharing development dividends with all shareholders[149]. Social Responsibility and Environmental Management - The company actively engaged in social responsibility by donating pharmaceuticals worth 602,000 CNY to the Gansu Province Veterans Care Foundation and the Gansu Province Women and Children Development Foundation[152]. - The company employed nearly 100 local farmers for medicinal herb processing, contributing to local employment and income generation[154]. - The company established a comprehensive environmental management system, achieving ISO 14001:2015 and ISO 45001:2018 certifications[146]. - The company has not faced any significant environmental pollution incidents or administrative penalties related to environmental issues during the reporting period[147]. - The company has developed an emergency plan for environmental risk events to minimize the occurrence of such incidents[146]. Future Outlook and Strategic Plans - The company aims to enhance its market presence in the Northwest and expand into the South China and international markets, focusing on a dual-driven model of traditional Chinese medicine and health industry[81]. - The 2025 operational plan emphasizes high-quality development, innovation, and digitalization, aligning with national strategic directives[82]. - The company targets five billion-yuan markets and four ten-million-yuan markets, aiming to boost sales through product diversification and market expansion[83]. - The company plans to strengthen brand management and expand its influence through cultural tourism and various advertising channels[83]. - The company is committed to developing new health products and enhancing existing ones, with ongoing research on two health products and four major varieties[88].

兰州佛慈制药股份有限公司 2025 年第一季度报告 证券代码：002644 证券简称：佛慈制药 公告编号：2025-009 兰州佛慈制药股份有限公司 2025 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： □是 否 1 兰州佛慈制药股份有限公司 2025 年第一季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第一季度报告是否经审计 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | | | | （%） | | 营业收入（元） | 216,124,672.92 | 274,329,503.97 | -21.22% | | 归属于上市公司股 ...

Core Viewpoint - The company reported a decline in both revenue and net profit for the year 2024, indicating potential challenges in its financial performance [1] Financial Performance - The company's operating revenue for 2024 was 980 million yuan, a year-on-year decrease of 15.73% [1] - The net profit attributable to shareholders was 60.0698 million yuan, down 10.60% compared to the previous year [1] - Basic earnings per share were 0.1176 yuan, reflecting a decline of 10.64% year-on-year [1] Dividend Distribution - The company plans to distribute a cash dividend of 0.12 yuan per 10 shares (tax included) to all shareholders [1] - No bonus shares will be issued, and there will be no capital reserve fund conversion into share capital [1]

证券代码：002644 证券简称：佛慈制药 公告编号：2025-003 根据《公司法》《公司章程》的有关规定，王迎春先生的辞职未导致公司董 事会成员低于法定人数，其辞职报告自送达董事会时生效，不会影响公司董事会 正常运作和公司正常生产经营。公司将按照法定程序尽快完成董事补选等相关工 作。 特此公告。 兰州佛慈制药股份有限公司董事会 2025 年 3 月 18 日 兰州佛慈制药股份有限公司 关于董事、副总经理辞职的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 兰州佛慈制药股份有限公司（以下简称"公司"）于 2025 年 3 月 18 日收到董 事、副总经理王迎春先生的书面辞职报告，王迎春先生因个人原因申请辞去公司 第八届董事会董事、副总经理以及董事会战略委员会委员职务。辞职后，王迎春 先生将不再担任公司任何职务。截至本公告披露日，王迎春先生未持有公司股份。 ...

Investment Rating - The report maintains a strong investment rating for the biopharmaceutical industry, particularly for the traditional Chinese medicine (TCM) sector, which is expected to benefit from multiple factors in 2025 [2]. Core Insights - The TCM sector is anticipated to experience a gradual reduction in performance pressure in 2025, driven by factors such as improved earnings, favorable policies, decreasing costs, rising demand, and consolidation within the industry [4][6]. - The report identifies five main investment opportunities within the TCM sector, including high-end OTC products, state-owned enterprise reforms, hospital-based TCM, dividend-paying assets, and turnaround situations for struggling companies [4][7]. Summary by Sections 1. Performance Outlook - The TCM sector faced overall revenue decline in 2024, with a total revenue of 270.61 billion yuan, down 3.28% year-on-year, and a net profit of 29.88 billion yuan, down 8.55% year-on-year [10]. - The number of companies forecasting negative net profit growth in 2024 is 22 out of 34, while only 12 companies expect positive growth [16]. 2. Policy Developments - The third batch of national TCM procurement results showed an average price reduction of 63%, but the impact on listed companies is limited due to the small number of affected products [20]. - A new essential drug list is expected to be released in 2025, which may include more TCM products, enhancing their market presence [24]. 3. Cost Factors - The TCM material price index has been declining since July 2024, which is expected to alleviate cost pressures for TCM companies and improve their gross margins starting in 2025 [28]. 4. Demand Dynamics - The recent increase in flu cases has driven demand for related treatment products, leading to a quicker clearance of inventory for cold and cough medications [34]. 5. Competitive Landscape - The TCM industry is experiencing frequent mergers and acquisitions, which are likely to enhance industry concentration and provide performance flexibility for related listed companies [39]. 6. Investment Opportunities - The report highlights five key investment themes: 1. High-end OTC TCM products, particularly those using natural bezoar as a key ingredient, are expected to see improved margins as supply stabilizes [45][54]. 2. State-owned enterprise reforms are anticipated to yield positive changes in management and strategic planning [7]. 3. Hospital-based TCM products are expected to gain market share due to regulatory support [7]. 4. Companies with strong cash flow and high dividend potential are viewed favorably [7]. 5. Companies currently facing challenges are expected to improve as inventory pressures ease [7]. 7. Recommended Stocks - The report suggests monitoring companies such as Kunming Pharmaceutical, Tongrentang, Darentang, Jiangzhong Pharmaceutical, Dong'e Ejiao, China Resources Sanjiu, Yunnan Baiyao, Tianshili, Fangsheng Pharmaceutical, and others for potential investment opportunities [4].

近日，公司收到陇南市文县市场监督管理局出具的《登记通知书》，陇南 佛慈纹党参公司已完成注销登记手续。 本次注销完成后，陇南佛慈纹党参公司将不再纳入公司合并报表范围，不 会对公司合并财务报表主要数据产生重大影响。本次注销是根据公司整体战略 规划考虑，有利于公司更好聚焦主业，降低管理成本，提高经营效率，不会对 公司整体业务发展和持续盈利能力产生重大影响，不存在损害公司及股东、特 别是中小股东利益的情形。 特此公告。 兰州佛慈制药股份有限公司董事会 证券代码：002644 证券简称：佛慈制药 公告编号：2025-002 兰州佛慈制药股份有限公司 关于控股子公司完成注销的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 兰州佛慈制药股份有限公司（以下简称"公司"）于 2024 年 10 月 25 日召开 第八届董事会第四次会议，审议通过了《关于注销控股子公司的议案》，同意 注销控股子公司陇南佛慈纹党参产业发展有限公司（以下简称"陇南佛慈纹党参 公司"），具体内容详见公司于 2024 年 10 月 26 日在《证券时报》《证券日报》 及巨潮资讯网（www.cninf ...

法律意见书 （2025）甘金律书字第 062 号 甘肃金城律师事务所 关于 兰州佛慈制药股份有限公司 2025 年第一次临时股东大会 之 二〇二五年一月十六日 1 / 6 甘肃金城律师事务所关于兰州佛慈制药股份有限公司 2025 年第一次临时股东大会之法律意见书 （2025）甘金律书字第 062 号 致：兰州佛慈制药股份有限公司 甘肃金城律师事务所（以下简称本所）受兰州佛慈制药股份有限公司（以下 简称公司或者贵公司）委托，就贵公司 2025 年第一次临时股东大会（以下简称 本次股东大会）召开的有关事宜，根据《中华人民共和国公司法》（以下简称《公 司法》）、《中华人民共和国证券法》（以下简称《证券法》）、《上市公司股 东大会规则》（以下简称《股东大会规则》）等有关法律、法规、规章、规范性 文件、交易所规则的规定，并依据《兰州佛慈制药股份有限公司章程》（以下简 称《公司章程》）的有关规定，本所指派律师列席贵公司本次股东大会，就本次 股东大会的召集、召开程序、现场出席会议人员资格、表决程序等相关事项进行 见证，并发表本《法律意见书》。 （一）为出具本《法律意见书》，本所律师除列席了本次股东大会，并核查 了贵公司提供 ...

证券代码：002644 证券简称：佛慈制药 公告编号：2025-001 兰州佛慈制药股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 重要提示： 1.本次股东大会无增加、变更、否决议案的情形； 2.本次股东大会不涉及变更前次股东大会决议。 一、会议召开情况和出席情况 1.会议召开情况 （1）会议召集人：董事会； （2）会议主持人：董事长单小东先生； （3）现场会议召开时间：2025 年 1 月 16 日（星期四）14：30 （4）现场会议召开地点：甘肃省兰州市兰州新区华山路 2289 号公司五楼会 议室； （5）会议召开方式：本次会议采用现场投票与网络投票表决相结合方式； 中小股东出席情况：通过现场和网络投票的中小投资者股东共 164 人，代表 股份 10,621,600 股，占公司有表决权总股份的 2.0800%。 （2）公司董事以及监事、高级管理人员列席了本次会议。 （3）甘肃金城律师事务所律师出席本次会议，对股东大会进行见证并出具 法律意见书。 二、议案审议表决情况 本次股东大会按照会议议程，采用记名方 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 兰州佛慈制药股份有限公司（以下简称"公司"）于 2024 年 12 月 30 日召开 第八届董事会第五次会议，审议通过了《关于提请召开 2025 年第一次临时股东 大会的议案》，本次股东大会的召开符合《公司法》《上市公司股东大会规则》等 法律法规、规范性文件及《公司章程》的有关规定。现就关于召开 2025 年第一 次临时股东大会的事项公告如下： 一、召开会议基本情况 1.股东大会届次：2025 年第一次临时股东大会 2.会议召集人：公司董事会 证券代码：002644 证券简称：佛慈制药 公告编号：2024-040 兰州佛慈制药股份有限公司 关于召开 2025 年第一次临时股东大会的通知 （2）网络投票：公司将通过深圳证券交易所交易系统和互联网投票系统 （http://wltp.cninfo.com.cn）向全体股东提供网络投票平台，股东可以在网络投 票时间内通过上述系统行使表决权。公司股东只能选择现场投票、网络投票中的 一种表决方式，如同一表决权出现重复表决的以第一次投票结果为准。 6.会议股权登记日：2025 ...